Oflodal en es it fr


Oflodal Marchi, Oflodal Analoghi

Oflodal Marchi miscela

  • No information avaliable
  • Oflodal Formula chimica


    Oflodal RX link


    Oflodal FDA foglio

    Oflodal FDA

    Oflodal DMS (foglio di materiale di sicurezza)

    Oflodal MSDS

    Oflodal Sintesi di riferimento

    I. Hayakava et al. US Pat. 4,382,892 (1983)

    Oflodal Peso molecolare

    361.368 g/mol

    Oflodal Temperatura di fusione

    250-257 oC

    Oflodal H2O Solubilita

    28,3 mg / ml

    Oflodal Stato


    Oflodal LogP


    Oflodal Forme di dosaggio

    Soluzione (IV iniezione); Tablet; gocce oftalmiche

    Oflodal Indicazione

    Per il trattamento di infezioni (tratto respiratorio, dei reni, pelle, tessuti molli, UTI), uretrale e cervicale gonorrea.

    Oflodal Farmacologia

    Ofloxacina è un chinolonico / fluorochinolone antibiotico. Ofloxacin è battericida e il suo modo di agire dipende il blocco della replicazione del DNA batterico da legarsi ad un enzima chiamato DNA girasi, che permette al untwisting necessario per replicare una doppia elica del DNA in due. In particolare il farmaco ha affinità 100 volte superiore per DNA girasi batterica rispetto a mammiferi. Ofloxacina è un ampio spettro antibiotico attivo contro i batteri sia Gram-positivi e Gram-negativi.

    Oflodal Assorbimento

    Biodisponibilità di ofloxacina nella formulazione in compresse è circa del 98%

    Oflodal Tossicita

    LD50 = 5450 mg / kg (per via orale nei topi)

    Oflodal Informazioni paziente

    Patients should be advised:

    - to drink fluids liberally;

    - that mineral supplements, vitamins with iron or minerals, calcium- , aluminum-, or magnesium-based
    antacids, sucralfate or Videx, (Didanosine), chewable/buffered tablets or the pediatric powder for
    oral solution should not be taken within the two-hour period before or within the two-hour period after
    taking ofloxacin (See Drug Interactions);

    - that ofloxacin can be taken without regard to meals;

    - that ofloxacin may cause neurologic adverse effects (e. g. , dizziness, lightheadedness) and that
    patients should know how they react to ofloxacin before they operate an automobile or machinery or
    engage in activities requiring mental alertness and coordination

    - to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture
    of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture
    has been confidently excluded;

    - that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to
    discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat,
    difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g. , swelling of the lips,
    tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction

    - to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue
    therapy if phototoxicity (e. g. , skin eruption) occurs;

    - that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue
    ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician

    - that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their
    physician before taking this drug if there is a history of this condition.

    Oflodal Atto interessato organismi

    Batteri enterici e altri eubatteri